100
Participants
Start Date
April 28, 2020
Primary Completion Date
March 5, 2028
Study Completion Date
April 28, 2028
Tyrosine Kinase Inhibitor
Targeted therapy given as standard of care.
Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
Given Q4 weeks as standard of care
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Given Q12 weeks for bone disease as standard of care
RECRUITING
University of Colorado Hospital, Aurora
RECRUITING
Lone Tree Medical Center, Lone Tree
Cancer League of Colorado
OTHER
University of Colorado, Denver
OTHER